Literature DB >> 17579073

The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation.

Diane Ordway1, Marcela Henao-Tamayo, Marisa Harton, Gopinath Palanisamy, Jolynn Troudt, Crystal Shanley, Randall J Basaraba, Ian M Orme.   

Abstract

The HN878 strain of Mycobacterium tuberculosis is regarded as "hypervirulent" due to its rapid growth and reduced survival of infected mice when compared with other clinical isolates. This property has been ascribed due to an early increase in type I IFNs and a failure to generate TH1-mediated immunity, induced by a response to an unusual cell wall phenolic glycolipid expressed by the HN878 isolate. We show, however, that although type I IFN does play an inhibitory role, this response was most apparent during the chronic disease stage and was common to all M. tuberculosis strains tested. In addition, we further demonstrate that the HN878 infection was associated with a potent TH1 response, characterized by the emergence of both CD4 and CD8 T cell subsets secreting IFN-gamma. However, where HN878 differed to the other strains tested was a subsequent reduction in TH1 immunity, which was temporally associated with the rapid emergence of a CD4+CD25+FoxP3+CD223+IL-10+ regulatory T cell population. This association may explain the paradoxical initial emergence of a TH1 response in these mice but their relatively short time of survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579073     DOI: 10.4049/jimmunol.179.1.522

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  131 in total

1.  Differential Mycobacterium bovis BCG vaccine-derived efficacy in C3Heb/FeJ and C3H/HeOuJ mice exposed to a clinical strain of Mycobacterium tuberculosis.

Authors:  Marcela Henao-Tamayo; Andrés Obregón-Henao; Elizabeth Creissen; Crystal Shanley; Ian Orme; Diane J Ordway
Journal:  Clin Vaccine Immunol       Date:  2014-11-12

2.  Importance of confirming data on the in vivo efficacy of novel antibacterial drug regimens against various strains of Mycobacterium tuberculosis.

Authors:  Mary A De Groote; Veronica Gruppo; Lisa K Woolhiser; Ian M Orme; Janet C Gilliland; Anne J Lenaerts
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

3.  Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Authors:  Natalie A Parlane; Katrin Grage; Jun Mifune; Randall J Basaraba; D Neil Wedlock; Bernd H A Rehm; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

4.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

5.  Does M. tuberculosis genomic diversity explain disease diversity?

Authors:  Mireilla Coscolla; Sebastien Gagneux
Journal:  Drug Discov Today Dis Mech       Date:  2010

6.  The impact of ISGylation during Mycobacterium tuberculosis infection in mice.

Authors:  Jacqueline M Kimmey; Jessica A Campbell; Leslie A Weiss; Kristen J Monte; Deborah J Lenschow; Christina L Stallings
Journal:  Microbes Infect       Date:  2017-01-10       Impact factor: 2.700

7.  Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells.

Authors:  Diane J Ordway; Shaobin Shang; Marcela Henao-Tamayo; Andres Obregon-Henao; Laura Nold; Megan Caraway; Crystal A Shanley; Randall J Basaraba; Colleen G Duncan; Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2011-07-27

Review 8.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

9.  Dominant role of the sst1 locus in pathogenesis of necrotizing lung granulomas during chronic tuberculosis infection and reactivation in genetically resistant hosts.

Authors:  Alexander V Pichugin; Bo-Shiun Yan; Alex Sloutsky; Lester Kobzik; Igor Kramnik
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

10.  Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate.

Authors:  Susan L Baldwin; Valerie A Reese; Po-Wei D Huang; Elyse A Beebe; Brendan K Podell; Steven G Reed; Rhea N Coler
Journal:  Clin Vaccine Immunol       Date:  2015-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.